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The involvement of the familial breast-ovarian cancer gene (BRCA1) i  the molecular pathogenesis of breast cancer
among Indian women is unknown. We have used a set of microsatellite polymorphisms to examine the frequency of
allele loss at the BRCA1 region on chromosome 17q21, in a panel of 80 human breast tumours. Tumour and blood
leukocyte/normal tissue DNA from a series of 80 patients with primary breast cancer was screened by PCR-amplified
microsatellite length polymorphisms to detect deletions at three polymorphic BRCA1 loci. PCR-allelotype was
valuable in examining allele losses from archival and small tumour samples. Loss of alleles at BRCA1 in the patient
set, confirmed a noteworthy role of this gene in the molecular pathogenesis of breast cancer and was in accordance
with its well-documented tumour suppressive function.
1. Introduction
Breast cancer although the second most common malignant
condition in India as a whole, ranks number one in the city
of Mumbai. The disease affects approximately 900 women in
Mumbai annually and is responsible for an annual age-
adjusted death rate of 30·1 per 100,000 (Notani 1997).
BRCA1 (the gene for breast cancer 1) localized on
chromosome 17q21 (Hall et l 1990), is a tumour suppressor
gene (Smith et al 1994; Friedman et al 1994; Neuhausen and
Marshall 1994; Merajver et al 1995). It is responsible for
both early onset breast and ovarian cancer, with 45% of
breast cancer families and 70% of breast-ovarian cancer
families linked to it (Easton et al 1993). Compared to other
racial groups, the Indians are different with respect to their
reproductive, dietary and environmental conditions. The
present study is directed towards finding out the extent of
BRCA1 involvement in the pathogenesis (rather than
initiation) of breast cancer among Indian patients by
assessing the rate of allele losses at this locus. This allelic
loss is termed as loss of heterozygosity (LOH) and is
demonstrated as a complete or partial reduction in the signal
intensity of one of the two corresponding alleles in tumour
DNA from patients heterozygous for a polymorphic marker.
The term “deletion” is often used where LOH is observed
regardless of the individual mechanism. In the presence of a
mutated tumour suppressor gene, loss of the normal
homologue unmasks the defective gene and allows
unopposed dysfunction. A second somatic event causing
loss of the normal homologue leads to tumorigenesis. This
event is accompanied by a large-scale chromosomal
deletion (Knudson 1971). The patient population includes
cases of sporadic primary breast cancer, cases presenting
with a family history of breast cancer and patients from the
Parsi population. The Parsis are an ethnic Indian group
presenting with a two and a half-fold higher relative
frequency of this disease. They are known to have a
westernized life-style and perhaps the differences in social,
cultural and environmental conditions may reflect an ethnic
variation in cancer occurrence in this group. Since family
history is known to pose a two- to three-fold increase in the
risk of b east cancer (Anderson 1992), this high-risk group
is studi d as a separate category. The effect of a gene with
a cancer family syndrome on the pathogenesis of the
disease in this group was thus studied separately.
2.  Materials and methods
2.1   Patient population
Eighty patients diagnosed with primary breast cancer who
belonged to one of the three following categories were
included in this study.
2.1a  Sporadic breast cancer (n=40):  No cancer of any
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kind in the relatives of the index case as checked from
medical records or personal correspondence.
2.1b  Familial breast cancer:  Where one first degree
relative or two second degree relatives other than the index
case were affected with breast cancer as checked from
medical records or personal correspondence.
2.1c  Parsi cases of breast cancer:  This category inclu-
ded primary breast cancer cases from the Parsi community
without any family history of the disease as confirmed from
medical records or personal correspondence.
  All these patients were treated at Tata Memorial Hospital,
Parel, Mumbai. Each of these patients presented with
unilateral breast cancer.
2.2  Normal and tumour tissue samples
For individuals of category (A), peripheral blood leukocytes
were obtained from each patient with informed consent and
used as a source of normal DNA, while they were being
treated at the hospital. For individuals of categories (B) and
(C), normal skin/lymph node paraffin sections served as the
source of obtaining normal DNA. Paraffin-embedded breast
tumours were used to extract tumour DNA for all three
groups. Each of the sections
of normal and paraffin-embedded tissues were checked
microscopically by haematoxylin-eosin staining. All samples
collected as sources of normal or tumour DNA were
obtained from the patient, before any kind of chemo-, radio-,
hormonal therapy was administered to her.
2.3  DNA isolation and estimation
DNA was extracted from peripheral blood lymphocytes
(Sambrook et al 1989) or paraffin-embedded tissues (Brow
1990) as per standard protocols. The samples were checked
by agarose gel electrophoresis, and their concentrati s
were estimated against a panel of densitometrically
estimated l  DNA standards.
2.4  Polymerase chain reaction
Polymesrase chain reaction (PCR) amplimers were generat d
using equal concentrations (50–100 ng) of genomic DNA
fro  matched normal and tumour samples. dNTP (2·5 mM
each) was used along with 0·2 mM of each of the
two primers and 1 unit of Taq polymerase per 50 ml
of reaction mix, 30–35 cycles of denaturation (94°C/
1 min), annealing (58°C or 55°C/1 min) and elongation
(72°C/1 min) were followed by a final elongation at
72°C/10 min. The PCR was standardized for each set of
primers used in the study. The primers and their sequenc s
are given in table 1.
2.5  LOH analysis
Fifteen ml of each PCR sample was loaded on a 15%
polyacrylamide gel with 3 ml of DNA gel loading dye. The
gel was run at a constant voltage of 150 V till the dye front
reached the bottom of the plates.
2.6  Silver staining
A rapid silver staining method (Neilan et al 1994) was used
to detect the bands. The gels were washed in deionized
water and fixed in 10% ethanol. They were then shaken in
1% nitric acid and thoroughly rinsed in deion ze  water.
Staining was continued in partial darkness, using a solution
of 3% sodium carbonate and 0·05% formaldehyde until the
desir d band intensity was achieved. Development was
stopped in 3% acetic acid and the gel was preserved in a
solution of 10% ethanol and 5% glycerol.
Table 1.  Microsatellite markers and their characteristics.
Locus   Primer         Sequence   Type
Annealing
temp.
(°C)
Average
product
size
No. of
alleles
Hetero-
zygosity
(%)       Reference
EDH-17B HSD-A3T 5¢-CAG TAC TAA AGG
CCC TAT TAT CAA A-3¢
5¢-AGG CTG CAG TGA
TTC CAG AT-3¢
AAAT 58 209 bp 2 18 Friedman et al  1993
Anderson et al 1993
D17S1322s754 5¢-CTA GCC TGG GCA
ACA AAC GA-3¢
5¢-GCA GGA AGC AGG
AAT GGA AC-3¢
(TTG)15 55 130 bp 7 67 Neuhausen et al
1994
D17S1323s975 5¢-TAG GAG ATG GAT
TAT TGG TG-3¢
5¢-AAG CAA CTT TGC
AAT GAG TG-3¢
(TG)19 55 155 bp 6 44 Neuhausen et al
1994
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3.  Results
Each case was represented by two samples (normal and
tumour) and was tested at each of the three BRCA1 loci for
LOH. Thus a total of 480 amplicons were subjected to
polyacrylamide gel electrophoresis. Frequencies of LOH in
our series of breast cancers varied according to the locus
tested. Tumours that were heterozygous (informative) for
any given locus were analysed for allele losses. LOH was
scored as a significant alteration in the relative allele
intensities between the two alleles from the tumour samples
compared to those from the normal as shown in the figure 1.
The figure represents a typical LOH, showing l ss of one
constitutive allele in the tumour sample. To calculate the
total loss at BRCA1 in each patient category, he number of
tumours informative at one or
more BRCA1 locus were noted. The percentage LOH at
BRCA1 was then calculated as the per cent of informative
tumours giving allele loss at any one of these loci. The
results are as follows:
(i)  Sporadic cases:  Collectively out of the 40 sporadic
tumours, 38 were informative at one or more loci and 23 of
these (60·53%) presented with LOH at at least one BRCA1
locus. Moreover out of these 23 tumours, four presented
losses simultaneously at more than one locus –two of them
showed losses at HSD-A3T and D17S1322, whereas two
others, at D17S1322 and D17S1323. Since the order of these
loci are cen-EDH17B (HSD-A3T)-D17S1322-D17S1323-tel; it
means that a large chunk of DNA in and around the gene
are lost in these patients.
(ii)  Familial cases:  Collectively out of 20 tumours
studied, 17 were informative at one or more loci and 7 out of
these 17 (41·18%) presented with LOH at at least one
BRCA1 locus. One case showed a loss simultaneously at
bo h intragenic loci.
(iii)  Parsi cases:  Collectively out of 20 tumours studied,
16 were informative at one or more loci. Overall, 6 out
of these 16 (35·71%) presented with LOH at any one BRCA1
locus.
(iv)  otal analysis of all cases:  Out of all 80 tumours
studied, 71 were informative at one or more loci. Overall, 36
out of these (50·70%) presented with LOH at any one
BRCA1 locus.
  Individual analysis of LOH at each of the three loci
in the different patient categories are represented in
tables 2–6.
4.  Discussion
The extent of BRCA1 involvement in the pathogenesis of
breast cancer among Indians is unknown. To the best of our
knowledge, our study is the first to address this question.
The patient population was subdivided into three groups
with different risks of breast cancer. It is known that
patients who have an affected first or second degree
relative with breast cancer are known to present with a two-
to three-fold increased risk of the disease (Anderson 1992).
The Parsis, an ethnic community
who settled in India about 1300 years ago from Persia rep-
resent a different study category for three reasons:
(i) They show a higher accumulation of secondary
risk factors, owing to their more westernized lifestyle.
(ii) They have a conserved genetic pool, owing to a high
frequency of consanguineous marriages. (iii) They present
with a 2·5-fold higher incidence of breast cancer, compar d
to age matched patients from other Indian communities
Figure 1.  LOH at D17S1322. Normal (N) DNA and tumour
(T) DNA from the same individual. Loss of one
constitutional allele in tumour DNA is shown by the
arrowhead.
Table 2.  LOH in sporadic cases.
Locus
Number of
tumours
studied
Number of
non-informative
tumours
Number of
informative
 tumours (x)
Tumours with
LOH
(y)
Percentage of tumours
with LOH
(y/x) 100
HSD-A3T 37 21 16   9 56·25
D17S1322 40 10 30 12 40·00
D17S1323 33   2 31   6 19·35
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(Jussawalla et al 1985). The sporadic cases represent a low-
risk group compared to the other two. This subdivision of
patient samples was done to determine whether the extent
of allelic loss at BRCA1 was different in different risk
populations. However we did not see a higher rate of
BRCA1 loss in the familial or Parsi cases compared to that
seen in the sporadic cases. This suggests that the
pathogenesis of breast cancer related to BRCA1 is the same
irrespective of risk of developing the disease.
  Allele losses previously reported in studies on sporadic
tumours have ranged from 21–59% (Futreal et al 1992; Sato
et al 1990; Cropp et al 1990, 1993; Kirchweger et al 1994;
Futreal et al 1994) with a high value of 79% LOH reported at
THRA1 (Futreal et al 1992). Another study report d an LOH
of 50%, using two intragenic and one extrag nic sequence
tagged repeats (STRs) (Futreal e  al 1994). A total LOH of
32% had been previously observed in a series of sporadic
tumours at the intragenic BRCA1 locus, D17S855 (Dillon et
al 1997). We report an overall loss of 60·53% in the BRCA1
region in the series of 40 sporadic tumours and losses of
18·6% and 40% at the two intragenic loci. A total of 43%
LOH was seen at both these loci collective y. Moreover four
s mples gave large-scale deletions at this region suggesting
deletion of all or part of the gene.
  BRCA1 loss was seen to an extent of 41·18% in the
familial cases. Studies over a span of four years have
revealed that 16–45% of breast-ovarian cancer families have
BRCA1 mutations (Easton et al 1993; Couch et al 1997).
  We have found a cumulative LOH of 37·5% at BRCA1 in
the 20 Parsi cases studied. Our estimates may be considered
as the “minimum estimates” on BRCA1 LOH analysis, since
our study has included three BRCA1 markers. This study
Table 3.  LOH in familial cases.
Locus
Number of
tumours
studied
Number of
non-informative
 tumours
Number of
informative
tumours (x)
Tumours with
LOH
(y)
Percentage of
tumours with LOH
(y/x) 100
HSD-A3T 19 13   6 3 50·00
D17S1322 20 13   7 5 71·42
D17S1323 19   5 14 1   7·14
Table 4.  LOH in Parsi cases.
Locus
Number of
tumours
studied
Number of
non-informative
tumours
Number of
informative
tumours (x)
Tumours with
 LOH
(y)
Percentage of
tumours with LOH
(y/x) 100
HSD-A3T 16 13   3 1 33·33
D17S1322 20 12   8 1 12·50
D17S1323 19   5 14 4 28·57
Table 5.  Total analysis of LOH in all patients.
Locus
Number of
tumours
studied
Number of
 non-informative
tumours
Number of
 informative
tumours (x)
Tumours with
LOH
(y)
Percentage of
tumours with LOH
(y/x) 100
HSD-A3T 72 47 25 13 52·00
D17S1322 80 35 45 18 40·00
D17S1323 71 12 59 11 18·60
Table 6.  Summary of LOH analysis in the three patient categories.
Patient
category
Number of
 tumours
studied
Number of
non-informative
tumours
Number of
informative
tumours (x)
Tumours with
 LOH
(y)
Percentage of
tumours with LOH
(y/x) 100
Sporadic cases 40 2 38 23 60·53
Familial cases 20 3 17   7 41·18
Parsi cases 20 4 16   6 37·50
Total analysis 80 9 71 36 50·70
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does not assess the risk of breast cancer associated with
BRCA1 in any of these three groups. Tumours were shown
to have allele loss at BRCA1, confirming its involvement in
the molecular pathogenesis of breast cancer and in keeping
with its well-documented role of a tumour suppressor gene.
Allele loss at BRCA1 is thus an important molecular event
in breast tumorigenesis among the Indians and is involved
to a high extent of about 50%.
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